BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:OpRegen readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of OpRegen\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05626114-11330@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20310301
DTEND;VALUE=DATE:20310302
SUMMARY:OpRegen: Phase 2 readout est. (NCT05626114)
DESCRIPTION:OpRegen\, phase 2\, Geographic Atrophy.\nStudy: A Study to Opti
 mize Subretinal Surgical Delivery and to Evaluate Safety and Activity of O
 pregen in Participants With Geographic Atrophy Secondary to Age-Related Ma
 cular Degeneration (GAlette)\; Adaptive Optics (AO) Retinal Imaging Substu
 dy in Association With Study GR44251\nEstimated primary completion: 1 Marc
 h 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/opregen#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05626114
URL:https://assetmemo.bio/drug/opregen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
